GILD examined a 6 week arm in the electron trial SVR rates were significantly lower (this is in naives non-cirrhotics) and conclusion was that this duration is not sufficient
patients in ELECTRON with compensated cirrhosis also didnt do as well without ribavirin (in contrast to LONESTAR) with 12 weeks - and authors concluded that for these patients ribavirin or a third DAA was probably necessary.
The arms were small in size, but still..all the focus (understandably) has been on LONESTAR results, but there were some small hiccups in data for sofosbuvir as noted above that got swept under the rug
note: i posted about this previously. none of this data at AASLD is really new - the abstracts have been out for some time except for updating SVR 3 to SVR 12 data
News 
Market Data 
Discover 
